Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
colistin + neomycin + fecal microbiota transplantation
- Development stage
- Unknown
- Lead developer
- Stephen Harbarth
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Nasogastric
01
Overview
This intervention is a sequential treatment protocol consisting of a 5-day course of oral non-absorbable antibiotics (colistin sulfate and neomycin sulfate) followed by fecal microbiota transplantation (FMT). Developed by Stephen Harbarth and colleagues as part of the R-GNOSIS WP3 study, it aims to decolonize the intestinal tract of patients carrying extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) and carbapenemase-producing Enterobacteriaceae (CPE). The antibiotics are intended to reduce the load of resistant bacteria, while the subsequent FMT (administered via nasogastric tube or capsules) restores a healthy gut microbiome to prevent recolonization. The trial was conducted across multiple centers in Europe and Israel.
- Other names
- Antibiotics and FMT for ESBL-E/CPE EradicationHarbarth FMT protocolFecal microbiota transplantation-Stephen Harbarth-Enterobacteriaceae colonization
02
Targets
Bacterial 50S ribosomal subunitBacterial Ribosome
Beyond the preview
Go deeper on colistin + neomycin + fecal microbiota transplantation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on colistin + neomycin + fecal microbiota transplantation.